WEBULL
WebtradeDownload

Denali Therapeutics Stock Earnings Beat Has The Bull Case Changed?

Simply Wall St · 1d ago
  • Denali Therapeutics reported Q3 2026 revenue of US$17.78 million and net income of US$70.13 million, with basic and diluted earnings per share from continuing operations of US$0.37 after a loss in the prior year period.
  • The newly launched Hunter syndrome therapy AVLAYAH delivered US$17.8 million of Q3 net product revenue, above prior guidance and supported by broad commercial and Medicaid coverage.
  • We will now look at how Denali Therapeutics' stronger than guided AVLAYAH revenue might influence the investment narrative around its platform.

Scan beyond Denali Therapeutics and line up other rare-disease and high-potential biotech plays using our hand-picked screener of 19 high quality undiscovered gems as a starting universe.

Denali Therapeutics Investment Narrative Recap

To own Denali Therapeutics, you need to buy into a simple idea. AVLAYAH is the commercial beachhead that supports a larger blood brain barrier platform, while a broad rare disease and neuro portfolio slowly works through the clinic. The latest quarter, with AVLAYAH revenue ahead of guidance and a swing to quarterly profit, speaks directly to that operating thesis.

The key near term catalyst is still AVLAYAH execution, especially payer coverage and sustained new starts in a small Hunter syndrome population. Management’s Q4 net product revenue outlook of US$30 million to US$32 million keeps attention squarely on whether early demand is repeatable. The biggest risk remains high ongoing R&D and SG&A against a still loss making nine month period.

The most relevant new disclosure for this story is the Q4 2026 net product revenue guidance of US$30 million to US$32 million. That range puts AVLAYAH’s next quarter under a spotlight. It gives you a concrete hurdle to watch as you track whether Q3’s performance was a one off spike or part of a steadier commercial build.

That guidance also ties directly into the broader Denali Therapeutics catalyst path. AVLAYAH cash flows help fund Sanfilippo candidate zafinofusp alfa ahead of a planned 2027 filing and support Alzheimer’s TransportVehicle programs that are expected to yield initial biomarker data the same year. Any shortfall against near term revenue expectations could make the current spend profile and timing of those later readouts feel more uncomfortable.

Denali Therapeutics’ current analyst narrative points to forecast 2029 revenue of US$378.3 million and earnings of US$63.9 million. This is based on an implied revenue growth rate that is described as very large at 371.7% per year and an earnings swing of about US$575.4 million, from a loss of US$511.5 million today to positive forecast consensus earnings in 2029.

Uncover why Denali Therapeutics' fair value indicates a 69% potential upside to its current price that may narrow quickly as sentiment catches up.

NasdaqGS:DNLI 1-Year Stock Price Chart
NasdaqGS:DNLI 1-Year Stock Price Chart

Exploring Other Perspectives

Some of the lowest Denali Therapeutics analysts focus on a different pressure point. They worry that heavy spending near US$97 million per quarter on R&D could overshadow AVLAYAH’s early Q3 profit, which was not in their models. Before this print, they were only pencilling in 2029 earnings of about US$26.0 million on US$162.6 million of revenue. That is far below the consensus view, so you should treat today’s surprise as a reason to compare these opposing stories and decide which assumptions feel closer to your own.

Explore 2 other Denali Therapeutics fair value estimates, including one that suggests up to 12% downside from the current price.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.

Looking For More Investment Ideas Beyond Denali Therapeutics?

Once you have a view on Denali Therapeutics, it can help to stress test your thinking against a wider watchlist. The Simply Wall St Screener lets you quickly scan for other companies with very different risk and return profiles, so you can see where Denali really fits in your overall plan.